Modulation of platelet-activating factor synthesis by recombinant interferon-alpha in human renal cell carcinoma.
Platelet-activating factor (PAF), a potent phospholipid chemical mediator of inflammation, is involved in multiple cellular functions. Since PAF has a strong effect on platelet aggregation and on the enhancement of capillary permeability, it is possible that this factor plays an important role in tumor progression. In human renal cell carcinoma (RCC), it has recently been reported that immunotherapy with interferon (IFN) is effective for the prevention of tumor recurrence and progression. To evaluate the role of PAF and the effect of interferon-alpha (IFN-alpha) on PAF production in RCC, we measured PAF content and the activity of choline phosphotransferase (CPT), an enzyme involved in the de novo biosynthesis of PAF, in RCC specimens obtained from 30 patients who had undergone radical nephrectomy for RCC, and in specimens of normal renal cortex and normal renal medulla. PAF was present in both RCC and the normal renal tissues. Although CPT activity in RCC was similar to that in normal renal cortex, CPT activity in the normal medulla was significantly higher than that in RCC and the normal cortex. No correlation was found between CPT activity and the pathological findings in RCC. Although there was no difference in CPT activity in normal renal tissues between patients treated preoperatively with IFN-alpha and those untreated, CPT activity in RCC was significantly reduced in patients who had received IFN-alpha compared with those who had not. These findings suggest that IFN-alpha may modulate the production of PAF in RCC patients.
Imagawa
M
M
Department of Urology, Oita Medical University, Japan.
Mimata
H
H
Takahashi
S
S
Nakagawa
M
M
Nomura
Y
Y
Ogata
J
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000628:therapy*; D003131:Combined Modality Therapy; D002798:Diacylglycerol Cholinephosphotransferase / Q000378:metabolism; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007668:Kidney / Q000378:metabolism; D007680:Kidney Neoplasms / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D010972:Platelet Activating Factor / Q000096:biosynthesis* / Q000187:drug effects; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010972:Platelet Activating Factor; D011994:Recombinant Proteins; D002798:Diacylglycerol Cholinephosphotransferase